Healthequity Inc’s recently made public that its Director SELANDER ROBERT W unloaded Company’s shares for reported $0.64 million on Feb 10 ’25. In the deal valued at $111.29 per share,5,750 shares were sold. As a result of this transaction, SELANDER ROBERT W now holds 78,219 shares worth roughly $8.2 million.
Then, ROBERT SELANDER bought 5,750 shares, generating $639,927 in total proceeds.
Before that, Elimelech Rosner bought 1,707 shares. Healthequity Inc shares valued at $166,508 were divested by the Officer at a price of $97.54 per share.
Mizuho initiated its Healthequity Inc [HQY] rating to an Outperform in a research note published on December 04, 2024; the price target was $126. A number of analysts have revised their coverage, including Goldman’s analysts, who began to cover the stock in mid November with a ‘”a Neutral”‘ rating. JMP Securities began covering HQY with “Mkt outperform” recommendation on April 04, 2024. JP Morgan maintained its rating on April 02, 2024. It rated HQY as “an Overweight”.
Price Performance Review of HQY
On Monday, Healthequity Inc [NASDAQ:HQY] saw its stock fall -4.50% to $104.82. Over the last five days, the stock has lost -4.21%. Healthequity Inc shares have risen nearly 9.24% since the year began. Nevertheless, the stocks have risen 26.29% over the past one year. While a 52-week high of $115.59 was reached on 02/13/25, a 52-week low of $65.01 was recorded on 01/02/25. SMA at 50 days reached $104.55, while 200 days put it at $89.00.
Levels Of Support And Resistance For HQY Stock
The 24-hour chart illustrates a support level at 102.12, which if violated will result in even more drops to 99.42. On the upside, there is a resistance level at 109.61. A further resistance level may holdings at 114.40. The Relative Strength Index (RSI) on the 14-day chart is 42.02, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -3.17, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 78.73%. Stochastics %K at 38.62% indicates the stock is a holding.
The most recent change occurred on January 03, 2024 when Barclays began covering the stock and recommended ‘”an Overweight”‘ rating along with a $84 price target.
